A systematic review and meta-analysis of bioresorbable vascular scaffolds for below-the-knee arterial disease.


Journal

International angiology : a journal of the International Union of Angiology
ISSN: 1827-1839
Titre abrégé: Int Angiol
Pays: Italy
ID NLM: 8402693

Informations de publication

Date de publication:
Feb 2021
Historique:
pubmed: 23 10 2020
medline: 31 8 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

Different types of bioresorbable vascular scaffolds (BVSs) have been developed and used in below-the-knee (BTK) arterial diseases. This is the first study reviewing and analyzing the literature on BVS treatment for BTK arterial disease. MEDLINE, Embase, and Cochrane were searched for studies published until October 21, 2019. The search, study selection, quality assessment, and data extraction were performed by 2 authors independently. Articles that studied the treatment of BTK arterial disease by using BVSs were eligible. Exclusion criteria were studies with a variant design (e.g. case reports <5 patients), non-BTK indications for BVS use, and nonhuman studies. Primary endpoint was 12-month primary patency. Secondary endpoints were 12-month freedom from clinically driven target lesion revascularization (CD-TLR), limb salvage, survival, and amputation-free survival (AFS). Study quality was assessed by the Methodological Index for Non-randomized Studies score. Five studies representing 155 patients with 160 treated limbs met the inclusion criteria. Pooled 12-month primary patency per limb was 90% (143/160; 95% confidence interval [CI]: 0.84-0.95), freedom from CD-TLR 96% (124/130; 95% CI: 0.91-0.99), limb salvage rate 97% (156/160; 95% CI: 0.94-1.00), survival rate 90% (112/125; 95% CI: 0.82-0.96), and AFS rate 89% (110/125; 95% CI: 0.81-0.94). Subgroup analyses of included Absorb BVS studies showed similar results. All studies were assessed as moderate quality. This meta-analysis of case series showed good 12-month patency and clinical results with BVSs for BTK arterial disease, even in patients with multimorbidity and short but complex lesions. These results encourage a revival of this scaffold.

Identifiants

pubmed: 33086777
pii: S0392-9590.20.04462-4
doi: 10.23736/S0392-9590.20.04462-4
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-51

Auteurs

Jetty Ipema (J)

Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands - j.ipema@nwz.nl.

Steven Kum (S)

Department of Surgery, Changi General Hospital, Singapore, Singapore.

Eline Huizing (E)

Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.

Michiel A Schreve (MA)

Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.

Ramon L Varcoe (RL)

Department of Surgery, Prince of Wales Hospital, Sydney, Australia.
Faculty of Medicine, University of New South Wales, Sydney, Australia.
The Vascular Institute, Prince of Wales Hospital, Sydney, Australia.

Constantijn E Hazenberg (CE)

Department of Vascular Surgery, University Medical Center (UMC) Utrecht, Utrecht, the Netherlands.

Jean-Paul DE Vries (JP)

Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen (UMCG), Groningen, the Netherlands.

Çağdaş ÜnlÜ (Ç)

Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH